FIELD: biotechnology.
SUBSTANCE: disclosed is a hybridoma cell ATCC PTA-9974, as well as an isolated antibody or its antigen-binding fragment, wherein antibody is obtained from a hybridoma cell according to invention and has CEACAM1 inhibitory activity. Also disclosed are, based on using disclosed antibody or its antigen-binding fragment: immunomodulation method; method of inhibiting migration or CEACAM1 expressing tumour cell proliferation; method of diagnosing cancer in an individual; method of treating or inhibiting cancer; as well as method of inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction and pharmaceutical composition for treating or inhibiting cancer.
EFFECT: antibody obtained from hybridoma according to present invention can find further application in therapy and diagnosis of various diseases related to CEACAM1.
18 cl, 8 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| ANTIBODIES SPECIFICALLY BINDING TYPE 1 RECEPTOR OF FIBROBLAST GROWTH FACTOR, ANTIBODIES APPLICATION FOR ONCOLOGICAL DISEASE TREATMENT, METHOD FOR ANTIBODIES PRODUCTION | 2015 |
|
RU2638457C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| POLYPEPTIDES AND POLYNUCLEOTIDES AND THEIR USE FOR TREATMENT OF IMMUNE DISORDERS AND CANCER | 2012 |
|
RU2623161C2 |
